Biodistribution of a novel ADC in tumor bearing mice

This study will examine the biodistribution pattern and pharmacokinetic properties of a novel antibody drug conjugate under development at Nordic Nanovector. These conjugates have not been tested previously in-vivo, and it is critical to their development that we understand their behavior inside a living animal bearing the human xenograft representative of the cancer they are designed to treat. By demonstrating the ADCs ability to seek out and bind to the tissue it is designed to target as well as not accumulating in sensitive organs that may lead to unwanted side effects of the drug we further its development into the efficacy phase of testing. We hypothesize that our ADC will have high uptake in the target organ (tumor) while having very little uptake and retention in the other organs collected